Commentary

Video

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses preliminary data from a phase 2 study (NCT05065554) of acalabrutinib (Calquence) plus rituximab (Rituxan) in patients with Waldenström’s Macroglobulinemia or IgM symptomatic anti-myelin associated glycoprotein (MAG)–mediated peripheral neuropathy.

The prospective, single-arm study was designed to evaluate the efficacy of BTK inhibition plus CD20 directed therapy as a novel treatment for patients with anti-MAG peripheral neuropathy, Castillo begins. Patients with an anti-MAG antibody and an IgM monoclonal gammopathy or Waldenström’s Macroglobulinemia; and a predominantly sensory demyelinating PN with a modified Rankin score of 1 or more with progressive symptoms or a score of 2 or more were enrolled onto the study. Treatment consisted of 100 mg of continuous oral acalabrutinib administered twice daily, plus weekly rituximab in cycles 1 and 4. The first 8 patients enrolled onto the study were included in this analysis. Interestingly, MYD88 mutations occurred in 6 patients but none were CXCR4 mutated, Castillo notes.

Results showed that the combination of acalabrutinib and rituximab demonstrated early activity in patients with IgM-related anti-MAG peripheral neuropathy, Castillo reports. Among the 7 evaluable patients, the overall response rate based on IWWM-11 criteria was 86%, he details. Categorical responses included 2 very good partial responses, 1 partial response, 3 minor responses, and 1 occurrence of stable disease. Additionally, 57% of patients showed improvement in their I-RODS score, with a median improvement of 0.5 points, he adds. The median time on treatment was 175 days (range 28-510), indicating a favorable duration of response.

Regarding safety, the treatment regimen was deemed well tolerated. However, 1 patient had to be removed from the trial after 28 days due to a grade 3 elevation in ALT. Two other grade 3 adverse effects occurred, including a rituximab-related infusion reaction and syncope unrelated to treatment, but these were deemed reversible.

Overall, these findings may provide a framework for the development of novel and more effective therapeutics in anti-MAG peripheral neuropathy, Castillo says. Additional data from more detailed neurologic assessments are expected to provide further insights, Castillo states, adding that long-term data will hopefully show that this regimen can induce responses to improve patients' quality of life. The trial is ongoing and enrollment continues.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP